WD Rutherford LLC Sells 1,336 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

WD Rutherford LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 56.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,050 shares of the company's stock after selling 1,336 shares during the quarter. WD Rutherford LLC's holdings in IDEXX Laboratories were worth $424,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter valued at about $30,000. Colonial Trust Co SC grew its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares during the last quarter. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $0.74 during trading on Wednesday, hitting $519.85. 590,930 shares of the company's stock traded hands, compared to its average volume of 649,056. The business has a 50 day moving average of $478.93 and a 200-day moving average of $445.88. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $536.78. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The stock has a market capitalization of $41.81 billion, a price-to-earnings ratio of 48.05, a PEG ratio of 3.80 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the previous year, the company earned $2.71 earnings per share. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on IDXX shares. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Stifel Nicolaus boosted their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Leerink Partners boosted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $546.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.